BBNX
Beta Bionics·NASDAQ
--
--(--)
--
--(--)
BBNX fundamentals
During Q4 2025, Beta Bionics (BBNX) reported revenue of 32.12M, a YoY change of 57.15%. Net income was -13.47M, a YoY change of 25.64%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 8.35M -- | 12.93M -- | 15.05M -- | 16.70M -- | 20.44M +144.79% | 17.64M +36.39% | 23.24M +54.45% | 27.25M +63.14% | 32.12M +57.15% | 100.25M -- |
Sales and Services Revenue | 8.35M -- | 12.93M -- | 15.05M -- | 16.70M -- | 20.44M +144.79% | 17.64M +36.39% | 23.24M +54.45% | 27.25M +63.14% | 32.12M +57.15% | 100.25M -- |
Cost of Revenue | 3.29M -- | 5.73M -- | 6.96M -- | 7.79M -- | 8.75M +166.15% | 8.67M +51.22% | 10.73M +54.19% | 12.13M +55.74% | 13.18M +50.58% | 44.71M -- |
Cost of Goods and Services | 3.29M -- | 5.73M -- | 6.96M -- | 7.79M -- | 8.75M +166.15% | 8.67M +51.22% | 10.73M +54.19% | 12.13M +55.74% | 13.18M +50.58% | 44.71M -- |
Gross Profit | 5.06M -- | 7.20M -- | 8.08M -- | 8.91M -- | 11.69M +130.92% | 8.97M +24.58% | 12.50M +54.66% | 15.12M +69.61% | 18.94M +62.07% | 55.54M -- |
Operating Expenses | 13.43M -- | 16.65M -- | 19.87M -- | 19.89M -- | 24.73M +84.12% | 27.61M +65.80% | 32.38M +62.95% | 32.16M +61.69% | 35.07M +41.83% | 127.22M -- |
Selling, General and Administrative Expenses | 8.97M -- | 11.18M -- | 13.52M -- | 14.75M -- | 15.51M +72.95% | 20.02M +79.18% | 23.50M +73.86% | 23.97M +62.49% | 24.94M +60.76% | 92.43M -- |
Selling and Marketing Expenses | 5.62M -- | 7.66M -- | 8.97M -- | 9.64M -- | 10.80M +92.31% | 13.40M +74.89% | 15.62M +74.09% | 16.05M +66.36% | 16.33M +51.18% | 61.40M -- |
General and Administrative Expenses | 3.35M -- | 3.51M -- | 4.54M -- | 5.11M -- | 4.71M +40.50% | 6.62M +88.53% | 7.88M +73.39% | 7.92M +55.18% | 8.60M +82.73% | 31.02M -- |
Research and Development Expenses | 4.46M -- | 5.48M -- | 6.35M -- | 5.14M -- | 9.21M +106.59% | 7.59M +38.53% | 8.87M +39.73% | 8.20M +59.40% | 10.13M +9.95% | 34.79M -- |
Operating Income | -8.37M -- | -9.45M -- | -11.78M -- | -10.98M -- | -13.04M -55.81% | -18.64M -97.21% | -19.87M -68.64% | -17.04M -55.26% | -16.12M -23.68% | -71.68M -- |
Non-Operating Income (Loss) | -10.48M -- | -3.00M -- | -2.68M -- | 1.24M -- | -5.07M +51.62% | -10.01M -234.25% | 3.00M +212.09% | 2.83M +128.36% | 2.66M +152.42% | -1.52M -- |
Gain (Loss) on Change in Fair Value | -9.96M -- | -4.14M -- | -3.67M -- | 419.00K -- | -6.02M +39.53% | -12.45M -200.80% | 0 +100.00% | 0 -100.00% | 0 +100.00% | -12.45M -- |
Other Non-Operating Income (Loss) | -1.77M -- | 4.00K -- | -2.00K -- | -4.00K -- | 0 +100.00% | 0 -100.00% | -2.00K -- | 1.00K +125.00% | 0 -- | -1.00K -- |
Net Interest Expense | -1.25M -- | -1.14M -- | -993.00K -- | -826.00K -- | -951.00K +23.98% | -2.44M -113.87% | -3.00M -202.62% | -2.83M -242.98% | -2.66M -179.50% | -10.93M -- |
Interest Income | 1.25M -- | 1.14M -- | 993.00K -- | 826.00K -- | 951.00K -23.98% | 2.44M +113.87% | 3.00M +202.62% | 2.83M +242.98% | 2.66M +179.50% | 10.93M -- |
Pretax Income From Continuing Operations | -18.85M -- | -12.45M -- | -14.46M -- | -9.74M -- | -18.11M +3.93% | -28.66M -130.19% | -16.87M -16.64% | -14.21M -45.94% | -13.47M +25.64% | -73.20M -- |
Net Income | -18.85M -- | -12.45M -- | -14.46M -- | -9.74M -- | -18.11M +3.93% | -28.66M -130.19% | -16.87M -16.64% | -14.21M -45.94% | -13.47M +25.64% | -73.20M -- |
Net Income Attributable to Owners of the Company | -18.85M -- | -12.45M -- | -14.46M -- | -9.74M -- | -18.11M +3.93% | -28.66M -130.19% | -16.87M -16.64% | -14.21M -45.94% | -13.47M +25.64% | -73.20M -- |
Net Income Attributable to Common Stockholders | -18.85M -- | -12.45M -- | -14.46M -- | -9.74M -- | -18.11M +3.93% | -28.66M -130.19% | -16.87M -16.64% | -14.21M -45.94% | -13.47M +25.64% | -73.20M -- |
Other Comprehensive Income | 137.00K -- | -132.00K -- | -26.00K -- | 79.00K -- | 7.00K -94.89% | 175.00K +232.58% | -91.00K -250.00% | 205.00K +159.49% | 49.00K +600.00% | 338.00K -- |
Total Comprehensive Income | -18.71M -- | -12.58M -- | -14.49M -- | -9.66M -- | -18.10M +3.26% | -28.48M -126.38% | -16.96M -17.05% | -14.00M -45.01% | -13.42M +25.88% | -72.86M -- |
Total Comprehensive Income Attributable to Owners of the Company | -18.71M -- | -12.58M -- | -14.49M -- | -9.66M -- | -18.10M +3.26% | -28.48M -126.38% | -16.96M -17.05% | -14.00M -45.01% | -13.42M +25.88% | -72.86M -- |
Basic EPS | -- -- | -2.07 -- | -2.37 -- | -1.46 -- | -- -- | -0.93 +55.07% | -0.39 +83.54% | -0.33 +77.40% | -0.3 -- | -1.95 -- |
Basic EPS from Continuing Operations | -- -- | -2.07 -- | -2.37 -- | -1.46 -- | -- -- | -0.93 +55.07% | -0.39 +83.54% | -0.33 +77.40% | -- -- | -- -- |
Diluted EPS | -- -- | -2.07 -- | -2.37 -- | -1.46 -- | -- -- | -0.93 +55.07% | -0.39 +83.54% | -0.33 +77.40% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -2.07 -- | -2.37 -- | -1.46 -- | -- -- | -0.93 +55.07% | -0.39 +83.54% | -0.33 +77.40% | -- -- | -- -- |
You can ask Aime
What is Beta Bionics's latest dividend and current dividend yield?What is Beta Bionics's gross profit margin?What guidance did Beta Bionics's management provide for the next earnings period?What is the market's earnings forecast for Beta Bionics next quarter?What does Beta Bionics do and what are its main business segments?What factors drove the changes in Beta Bionics's revenue and profit?Did Beta Bionics beat or miss consensus estimates last quarter?What were the key takeaways from Beta Bionics’s earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
